Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study | Synapse
April 13, 2026
Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study
MC
Marley Cutrona
Mount Sinai Hospital
SG
Sophie Guénin
MK
Mindy Kresch‐Vatch
Ver todo
Puntos clave
The study aims to evaluate the effectiveness of JAK and TYK2 inhibitors for treating psoriasis-eczema overlap.
Retrospective analysis of patient records
Assessment of treatment outcomes with JAK and TYK2 inhibitors
Comparison of symptom improvement scores
Positive trends observed in symptom reduction
Improvement noted in skin lesion severity
Increased patient satisfaction with treatment outcomes
Resumen
Research data are not shared.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Cutrona et al. (Fri,) studied this question.
synapsesocial.com/papers/69dc87ea3afacbeac03e9f76
https://doi.org/https://doi.org/10.1111/ijd.70393
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir